Pathstone Family Office’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $1.43M | Buy |
5,576
+4,055
| +267% | +$1.08M | 0.01% | 570 |
|
|
2023
Q2 | $455K | Buy |
1,521
+203
| +15% | +$60.4K | 0.01% | 793 |
|
|
2023
Q1 | $366K | Sell |
1,318
-4,526
| -77% | -$1.25M | 0.01% | 825 |
|
|
2022
Q4 | $1.37M | Buy |
5,844
+983
| +20% | +$278K | 0.01% | 643 |
|
|
2022
Q3 | $1.3M | Buy |
4,861
+3,149
| +184% | +$669K | 0.01% | 620 |
|
|
2022
Q2 | $349K | Buy |
1,712
+173
| +11% | +$35.4K | 0.01% | 725 |
|
|
2022
Q1 | $325K | Buy |
1,539
+21
| +1% | +$4.57K | 0.01% | 718 |
|
|
2021
Q4 | $365K | Buy |
1,518
+629
| +71% | +$162K | 0.01% | 651 |
|
|
2021
Q3 | $251K | Sell |
889
-10
| -1% | -$3.28K | 0.01% | 730 |
|
|
2021
Q2 | $311K | Buy |
899
+91
| +11% | +$27.6K | 0.01% | 632 |
|
|
2021
Q1 | $226K | Buy |
808
+248
| +44% | +$66.9K | 0.01% | 571 |
|
|
2020
Q4 | $137K | Buy |
560
+107
| +24% | +$27.6K | 0.01% | 332 |
|
|
2020
Q3 | $128K | Hold |
453
| – | – | 0.01% | 243 |
|
|
2020
Q2 | $122K | Sell |
453
-321
| -41% | -$96.5K | 0.01% | 200 |
|
|
2020
Q1 | $244K | Buy |
774
+607
| +363% | +$184K | 0.03% | 150 |
|
|
2019
Q4 | $496K | Hold |
167
| – | – | 0.01% | 299 |
|
|
2019
Q3 | $39K | Hold |
167
| – | – | 0.01% | 304 |
|
|
2019
Q2 | $39K | Sell |
167
-360
| -68% | -$83.1K | ﹤0.01% | 359 |
|
|
2019
Q1 | $124K | Buy |
527
+10
| +2% | +$3.15K | 0.02% | 213 |
|
|
2018
Q4 | $155K | Hold |
517
| – | – | 0.04% | 99 |
|
|
2018
Q3 | $182K | Buy |
517
+50
| +11% | +$17.2K | 0.06% | 56 |
|
|
2018
Q2 | $136K | Sell |
467
-50
| -10% | -$14.1K | 0.1% | 54 |
|
|
2018
Q1 | $142K | Buy |
517
+150
| +41% | +$46.6K | 0.08% | 56 |
|
|
2017
Q4 | $117K | Sell |
367
-83
| -18% | -$26.6K | 0.06% | 44 |
|
|
2017
Q3 | $120K | Sell |
450
-117
| -21% | -$34.6K | 0.11% | 51 |
|
|
2017
Q2 | $153K | Buy |
567
+195
| +52% | +$51.6K | 0.06% | 121 |
|
|
2017
Q1 | $102K | Buy |
+372
| New | +$105K | 0.06% | 129 |
|
|
2016
Q4 | – | Sell |
-367
| Closed | -$115K | – | 109 |
|
|
2016
Q3 | $115K | Hold |
367
| – | – | 0.12% | 39 |
|
|
2016
Q2 | $88K | Hold |
367
| – | – | 0.08% | 41 |
|
|
2016
Q1 | $95K | Buy |
367
+312
| +567% | +$82.4K | 0.19% | 34 |
|
|
2015
Q4 | $17K | Buy |
+55
| New | +$15.8K | 0.08% | 35 |
|
|
2014
Q4 | – | Sell |
-113
| Closed | -$37K | – | 127 |
|
|
2014
Q3 | $37K | Buy |
+113
| New | +$37.3K | 0.11% | 68 |
|
Other funds holding BIIB
Pathstone Family Office's BIIB Position: Q3 2023 in Review
Pathstone Family Office increased its Biogen (BIIB) stake by 267% in Q3 2023, buying an estimated $1.08M and bringing the position to 5,576 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #570.
Pathstone Family Office first reported a position in BIIB in Q3 2014 and has held it in 32 quarters since. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.
- Pathstone Family Office held 5,576 shares of Biogen worth $1.43M as of Q3 2023.
- Pathstone Family Office bought 4,055 Biogen shares in Q3 2023, an estimated $1.08M.
- Biogen made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #570 holding.
- Pathstone Family Office first reported a position in Biogen in Q3 2014 and has held it in 32 quarters since.
- 965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.